Literature DB >> 28892121

Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men.

Ariela R Orkaby1,2, J Michael Gaziano1,2,3, Luc Djousse1,2,3, Jane A Driver1,2.   

Abstract

BACKGROUND/
OBJECTIVES: We sought to determine whether statin use for primary prevention is associated with a lower risk of cardiovascular events or mortality in older men.
DESIGN: Prospective cohort study.
SETTING: Physicians' Health Study participants. PARTICIPANTS: 7,213 male physicians ≥70 years without a history of cardiovascular disease (CVD). MEASUREMENTS: Multivariable propensity score for statin use with greedy matching (1:1) to minimize confounding by indication.
RESULTS: Median baseline age was 77 (70-102), median follow-up was 7 years. Non-users were matched to 1,130 statin users. Statin use was associated with an 18% lower risk of all-cause mortality, HR 0.82 (95% CI 0.69-0.98) and non-significant lower risk of CVD events, HR 0.86 (95% CI 0.70-1.06) and stroke, HR 0.70 (95% CI 0.45-1.09). In subgroup analyses, results did not change according to age group at baseline (70-76 or >76 years) or functional status. There was a suggestion that those >76 at baseline did not benefit from statins for mortality, HR 1.14 (95% CI 0.89-1.47), compared to those 70-76 at baseline, HR 0.83 (95% CI 0.61-1.11); however the CIs overlap between the two groups, suggesting no difference. Statin users with elevated total cholesterol had fewer major CVD events than non-users, HR 0.68 (95% CI 0.50-0.94) and HR 1.43 (95% CI 0.99-2.07)), respectively.
CONCLUSIONS: Statin use was associated with a significant lower risk of mortality in older male physicians ≥70 and a nonsignificant lower risk of CVD events. Results did not change in those who were >76 years at baseline or according to functional status. There was a suggestion that those with elevated total cholesterol may benefit. Further work is needed to determine which older individuals will benefit from statins as primary prevention.
© 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics Society.

Entities:  

Keywords:  aging; cardiovascular disease; prevention; statins

Mesh:

Substances:

Year:  2017        PMID: 28892121      PMCID: PMC5681374          DOI: 10.1111/jgs.14993

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  39 in total

1.  Statin discontinuation in nursing home residents with advanced dementia.

Authors:  Jennifer Tjia; Sarah L Cutrona; Daniel Peterson; George Reed; Susan E Andrade; Susan L Mitchell
Journal:  J Am Geriatr Soc       Date:  2014-11-04       Impact factor: 5.562

2.  Beyond information: exploring patients' preferences.

Authors:  Ronald M Epstein; Ellen Peters
Journal:  JAMA       Date:  2009-07-08       Impact factor: 56.272

Review 3.  Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials.

Authors:  Donna M Zulman; Jeremy B Sussman; Xisui Chen; Christine T Cigolle; Caroline S Blaum; Rodney A Hayward
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

4.  Use of Statins in Adults Older Than 75 Years-Reply.

Authors:  Jerry H Gurwitz; Alan S Go; Stephen P Fortmann
Journal:  JAMA       Date:  2017-03-14       Impact factor: 56.272

5.  Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1988-01-28       Impact factor: 91.245

6.  Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.

Authors:  Michelle C Odden; Mark J Pletcher; Pamela G Coxson; Divya Thekkethala; David Guzman; David Heller; Lee Goldman; Kirsten Bibbins-Domingo
Journal:  Ann Intern Med       Date:  2015-04-21       Impact factor: 25.391

7.  Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

Authors:  Robert J Glynn; Wolfgang Koenig; Børge G Nordestgaard; James Shepherd; Paul M Ridker
Journal:  Ann Intern Med       Date:  2010-04-20       Impact factor: 25.391

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

Review 10.  Evaluation and treatment of older patients with hypercholesterolemia: a clinical review.

Authors:  Timo E Strandberg; Laura Kolehmainen; Alpo Vuorio
Journal:  JAMA       Date:  2014-09-17       Impact factor: 56.272

View more
  11 in total

Review 1.  Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines.

Authors:  Chelsea E Hawley; John Roefaro; Daniel E Forman; Ariela R Orkaby
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

2.  Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.

Authors:  Ariela R Orkaby; Jane A Driver; Yuk-Lam Ho; Bing Lu; Lauren Costa; Jacqueline Honerlaw; Ashley Galloway; Jason L Vassy; Daniel E Forman; J Michael Gaziano; David R Gagnon; Peter W F Wilson; Kelly Cho; Luc Djousse
Journal:  JAMA       Date:  2020-07-07       Impact factor: 56.272

3.  Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015).

Authors:  Sunyoung Kim; Hangseok Choi; Chang Won Won
Journal:  Ann Geriatr Med Res       Date:  2020-06-29

Review 4.  Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making.

Authors:  Sonal Singh; Susan Zieman; Alan S Go; Stephen P Fortmann; Nanette K Wenger; Jerome L Fleg; Barbara Radziszewska; Neil J Stone; Sophia Zoungas; Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2018-10-02       Impact factor: 5.562

5.  Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.

Authors:  Ariela R Orkaby; Michael W Rich; Ryan Sun; Eliah Lux; Lee-Jen Wei; Dae Hyun Kim
Journal:  J Am Geriatr Soc       Date:  2018-09-25       Impact factor: 5.562

6.  Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

Authors:  Kari Luotola; Satu Jyväkorpi; Annele Urtamo; Kaisu H Pitkälä; Mika Kivimäki; Timo E Strandberg
Journal:  Age Ageing       Date:  2020-02-27       Impact factor: 10.668

Review 7.  Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients.

Authors:  Timo E Strandberg
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

8.  Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.

Authors:  Philippe Giral; Anke Neumann; Alain Weill; Joël Coste
Journal:  Eur Heart J       Date:  2019-11-14       Impact factor: 29.983

Review 9.  Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.

Authors:  Lauren J Hassen; Steven R Scarfone; Michael Wesley Milks
Journal:  Geriatrics (Basel)       Date:  2022-03-25

10.  Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Authors:  Kamal Awad; Maged Mohammed; Mahmoud Mohamed Zaki; Abdelrahman I Abushouk; Gregory Y H Lip; Michael J Blaha; Carl J Lavie; Peter P Toth; J Wouter Jukema; Naveed Sattar; Maciej Banach
Journal:  BMC Med       Date:  2021-06-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.